论文信息 - Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG). - 字舞流文

Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).

E. Lipp | H. Friedman | A. Desjardins | J. Vredenburgh | J. Herndon | M. Affronti | K. Peters | V. Poillucci | F. McSherry | S. Cheshire | Jung-Young Kim | Christina K. Cone | W. Massey | Elizabeth S. Miller | C. Southerland | K. Kalinowski | A. Brickhouse | H. H. Lay | J. Tetterton